SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Wilma Rudolph Synthetic CCD

PatientWilma Rudolph
Date of birth1972-06-23
IdentifiersMRN HR-ML036-SYN; SSN (made up) 000-36-5170
Document date2026-11-01
AuthorGloria Haynes-Whitaker, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New headaches, word-finding pauses and right-hand clumsiness in a woman of 54: neurologic examination, MRI of the brain booked for the next morning, and neuro-oncology review booked. Concerns: Headaches on waking for three weeks, now most mornings; words that will not come for ten days; dropping things from the right hand; She wants the cause found quickly and explained plainly, without being talked around; She worries about falling and about losing her independence: her left leg was the weak one when she was a child, and now her right hand is clumsy. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2026-06-29activeS
Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgeryOne tablet twice a day with breakfast and lunchOral route2026-06-30 to 2026-07-08completedS
Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasoneOne tablet twice a dayOral route2026-06-30 to 2026-08-12completedS
Dexamethasone 2 mg oral tablet, one tablet twice a day after surgery, taperingOne tablet twice a dayOral route2026-07-10 to 2026-07-29completedS
Dexamethasone 2 mg oral tablet: one tablet daily for one week, then half a tablet daily for one week, then stopOne tablet daily for a week, then half a tablet daily for a weekOral route2026-07-29 to 2026-08-12completedS
Temozolomide 140 mg oral capsule, 140 mg (75 mg/m2) by mouth daily at bedtime on an empty stomach, seven days a week for 42 days from the first day of radiotherapyOnce daily at bedtime, seven days a week, for 42 daysOral route2026-08-03 to 2026-09-13completedS
Sulfamethoxazole 800 mg and trimethoprim 160 mg oral tablet, one tablet three times a week (Monday, Wednesday and Friday) to prevent Pneumocystis pneumoniaOne tablet on Monday, Wednesday and FridayOral route2026-08-03activeS
Ondansetron 8 mg oral tablet, one tablet 30 to 60 minutes before each temozolomide dose, and every 8 hours as needed for nauseaBefore each temozolomide dose; every 8 hours as neededOral route2026-08-03activeS
Temozolomide 140 mg oral capsule, 280 mg (150 mg/m2) by mouth at bedtime on days 1 to 5 of each 28-day cycle, adjuvant cycle 1 of 6Two capsules once daily at bedtime on days 1 to 5 of each 28-day cycleOral route2026-10-09activeS

Procedures

ProcedureDatesStatusEvidence
MRI of the brain with and without contrast, with diffusion and perfusion: a 3.8 x 3.2 cm ring-enhancing mass in the left posterior frontal lobe, involving the posterior inferior frontal gyrus and abutting the precentral gyrus, with central necrosis, raised relative cerebral blood volume in the enhancing rim, no restricted diffusion in the necrotic center, surrounding FLAIR signal from edema, and 5 mm rightward midline shift; no other lesion2026-06-30 to 2026-06-30completedS
CT of the chest, abdomen and pelvis with contrast to look for a primary cancer elsewhere: no mass, enlarged lymph node or other lesion2026-07-01 to 2026-07-01completedS
Functional MRI with diffusion tensor tractography for surgical planning: left-hemisphere language dominance; expressive language activation just in front of the mass; the corticospinal tract displaced but intact2026-07-06 to 2026-07-06completedS
Awake left frontal craniotomy with cortical and subcortical language and motor mapping and fluorescence-guided resection: gross total resection of the enhancing tumor, stopped at the mapped language sites. Pathology: glioblastoma, IDH-wildtype, CNS WHO grade 4 (necrosis and microvascular proliferation; IDH1 R132H immunostain negative and no IDH1 or IDH2 mutation on sequencing; ATRX retained; TERT promoter mutation; EGFR amplification; gain of chromosome 7 and loss of chromosome 10; CDKN2A homozygous deletion; histone H3 and BRAF wild-type). MGMT promoter methylated by pyrosequencing. Inpatient stay of three days, with mechanical and then low-molecular-weight heparin prophylaxis against venous thromboembolism from the day after surgery2026-07-08 to 2026-07-08completedS
MRI of the brain with and without contrast within 48 hours of surgery: no residual enhancing tumor; expected postoperative blood products; small area of restricted diffusion at the posterior margin from surgery; edema and midline shift less2026-07-09 to 2026-07-09completedS
Outpatient physical therapy assessment: mild weakness of the right hand and hip flexors after surgery; the left calf, weakened by polio in childhood, slightly smaller than the right with full strength; Timed Up and Go 9 seconds; home exercise program, home safety review and a fall plan2026-07-22 to 2026-07-22completedS
External beam radiotherapy to the resection cavity and margin, 60 Gy in 30 daily fractions over six weeks, with daily temozolomide; given in full on schedule2026-08-03 to 2026-09-11completedS
Outpatient palliative care consultation alongside cancer treatment: symptoms, coping, her understanding of the illness, goals and wishes, support for her family, and advance care planning; she named a health care agent (recorded in the confidential part of the chart) and completed an advance directive2026-09-28 to 2026-09-28completedS
MRI of the brain with and without contrast four weeks after chemoradiation: thin, smooth enhancement along the resection cavity with no nodular or new enhancement; FLAIR change around the cavity slightly less than after surgery; no new lesion. Treatment-related change; no progression (RANO 2.0); this scan is the new baseline2026-10-07 to 2026-10-07completedS
Advance care planning conversation, about 20 minutes, reviewing the advance directive completed with palliative care2026-10-29 to 2026-10-29completedS

Immunizations

DateVaccineStatusEvidence
2026-10-29Influenza vaccine, inactivated, trivalent, preservative free, this seasoncompletedS
2026-10-29Pneumococcal conjugate vaccine PCV20completedS
2026-10-29Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
June 23, 1940Born prematurely, weighing about 4.5 poundsD (CLM-0002)
about 1944Double pneumonia followed by scarlet fever at about age four, among other childhood illnessesD (CLM-0003)
about 1945Poliomyelitis in early childhood, leaving the left leg paralyzed or partly paralyzed, with the foot turned inwardD (CLM-0004)
about 1946Metal leg brace and special shoe for several years; weekly treatment at Meharry Medical College in Nashville, with massage and heat, and massage at home several times a dayD (CLM-0005)
about 1952Walking without the brace by about age 12; later an Olympic sprinterD (CLM-0006, CLM-0007)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Headaches on waking for three weeks, now most mornings; words that will not come for ten days; dropping things from the right handactiveS
She wants the cause found quickly and explained plainly, without being talked aroundactiveS
She worries about falling and about losing her independence: her left leg was the weak one when she was a child, and now her right hand is clumsyactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 11.8 on 2026-10-29; Leukocytes [#/volume] in Blood by Automated count 3.4 on 2026-10-29; Platelets [#/volume] in Blood by Automated count 121 on 2026-10-29; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-07-02; Potassium [Moles/volume] in Serum or Plasma 4 on 2026-07-02; Creatinine [Mass/volume] in Serum or Plasma 0.81 on 2026-10-09; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 86 on 2026-10-09; Glucose [Mass/volume] in Serum or Plasma 91 on 2026-10-09; Hemoglobin A1c/Hemoglobin.total in Blood 5.6 on 2026-06-29; Karnofsky Performance Status score 80 on 2026-10-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-29; INR in Platelet poor plasma by Coagulation assay 1 on 2026-07-02; aPTT in Blood by Coagulation assay 29 on 2026-07-02; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 2026-10-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 9 on 2026-07-02; Neutrophils [#/volume] in Blood by Automated count 1.9 on 2026-10-29; Lymphocytes [#/volume] in Blood by Automated count 0.6 on 2026-10-29; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 2026-10-29; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-10-29; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-10-09; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-07-29 [S]

Strengths and supports: Vice president of a Nashville hospital; former Olympic champion sprinter, teacher and coach; runs a foundation that supports young track and field athletes [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Three weeks of headaches on waking, with ten days of pauses in finding words and clumsiness of the right hand, in a previously well woman of 54: an intracranial lesion must be excluded. MRI of the brain with and without contrast booked for tomorrow morning, and neuro-oncology review bookedresolvedconfirmed R29.818S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded when the MRI showed a brain mass.
Left posterior frontal ring-enhancing mass, 3.8 cm, with central necrosis, surrounding edema and 5 mm midline shift, next to the language and motor areas; presumed high-grade glioma, with no primary cancer elsewhere on CT; tissue diagnosis pendingresolvedconfirmed D49.6S — Synthetic imaging diagnosis before surgery; superseded by the pathology.
Glioblastoma, IDH-wildtype, CNS WHO grade 4, left posterior frontal lobe, MGMT promoter methylated, after gross total resection of the enhancing tumor; synthetic modern detail linked to her publicly reported brain canceractiveconfirmed C71.1S — Synthetic histology, molecular result and location; brain cancer is documented as the cause of her death (D), and nothing more about it was made public.
Late effects of childhood poliomyelitis: paralysis of the left leg in early childhood, treated with a metal brace, a special shoe, massage and heat, with full recovery of walking by about age 12 and a later career as an Olympic sprinter; no new weakness, fatigue or pain now to suggest post-polio syndromeactiveconfirmed B91S — Documented childhood polio (D); the current absence of new symptoms is synthetic.
Vasogenic cerebral edema around the left frontal mass, with 5 mm midline shift, causing headache and contributing to the language and right-hand symptoms; treated with dexamethasoneresolvedconfirmed G93.6S — Synthetic finding on the first MRI.
Steroid-induced hyperglycemia on dexamethasone: random glucose 168 mg/dL, with an A1c of 5.6% before steroidsresolvedconfirmed R73.9S — Synthetic common effect of dexamethasone; resolved after the taper.
Lymphopenia from temozolomide, grade 2 (absolute lymphocytes 0.5 x 10^3/uL at the end of chemoradiation): Pneumocystis prophylaxis continues until recovery to grade 1 or betteractiveconfirmed D72.810S — Synthetic common effect of daily temozolomide with radiotherapy.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-06-29Hemoglobin [Mass/volume] in Blood13.1g/dL12-15.5 g/dLNormalS
2026-06-29Leukocytes [#/volume] in Blood by Automated count7.110*3/uL4-11 10*3/uLNormalS
2026-06-29Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
2026-06-29Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-06-29Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-06-29Creatinine [Mass/volume] in Serum or Plasma0.86mg/dL0.59-1.04 mg/dLNormalS
2026-06-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M80mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-06-29Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2026-06-29Hemoglobin A1c/Hemoglobin.total in Blood5.6%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
2026-06-29Karnofsky Performance Status score80{score}S
2026-06-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-07-02Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
2026-07-02Leukocytes [#/volume] in Blood by Automated count11.810*3/uL4-11 10*3/uLHighS
2026-07-02Platelets [#/volume] in Blood by Automated count27010*3/uL150-400 10*3/uLNormalS
2026-07-02Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-07-02Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
2026-07-02Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.59-1.04 mg/dLNormalS
2026-07-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-02Glucose [Mass/volume] in Serum or Plasma138mg/dL70-99 mg/dLHighS
2026-07-02INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
2026-07-02aPTT in Blood by Coagulation assay29s25-37 sNormalS
2026-07-02Karnofsky Performance Status score80{score}S
2026-07-02Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-07-02Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]9{score}S
2026-07-29Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-07-29Leukocytes [#/volume] in Blood by Automated count9.610*3/uL4-11 10*3/uLNormalS
2026-07-29Neutrophils [#/volume] in Blood by Automated count7.210*3/uL1.5-7.7 10*3/uLNormalS
2026-07-29Lymphocytes [#/volume] in Blood by Automated count1.110*3/uL1-4 10*3/uLNormalS
2026-07-29Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-07-29Creatinine [Mass/volume] in Serum or Plasma0.82mg/dL0.59-1.04 mg/dLNormalS
2026-07-29Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M85mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-35 U/LNormalS
2026-07-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
2026-07-29Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-07-29Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-07-29Glucose [Mass/volume] in Serum or Plasma168mg/dL70-99 mg/dLHighS
2026-07-29Karnofsky Performance Status score90{score}S
2026-07-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-09-14Hemoglobin [Mass/volume] in Blood11.9g/dL12-15.5 g/dLLowS
2026-09-14Leukocytes [#/volume] in Blood by Automated count3.610*3/uL4-11 10*3/uLLowS
2026-09-14Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.5-7.7 10*3/uLNormalS
2026-09-14Lymphocytes [#/volume] in Blood by Automated count0.510*3/uL1-4 10*3/uLLowS
2026-09-14Platelets [#/volume] in Blood by Automated count11210*3/uL150-400 10*3/uLLowS
2026-09-14Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-09-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M88mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-09-14Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma48U/L7-35 U/LHighS
2026-09-14Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma39U/L8-35 U/LHighS
2026-09-14Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
2026-09-14Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
2026-09-14Karnofsky Performance Status score80{score}S
2026-09-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2026-10-09Hemoglobin [Mass/volume] in Blood12.2g/dL12-15.5 g/dLNormalS
2026-10-09Leukocytes [#/volume] in Blood by Automated count4.410*3/uL4-11 10*3/uLNormalS
2026-10-09Neutrophils [#/volume] in Blood by Automated count2.910*3/uL1.5-7.7 10*3/uLNormalS
2026-10-09Lymphocytes [#/volume] in Blood by Automated count0.610*3/uL1-4 10*3/uLLowS
2026-10-09Platelets [#/volume] in Blood by Automated count16810*3/uL150-400 10*3/uLNormalS
2026-10-09Creatinine [Mass/volume] in Serum or Plasma0.81mg/dL0.59-1.04 mg/dLNormalS
2026-10-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M86mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
2026-10-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
2026-10-09Bilirubin.total [Mass/volume] in Serum or Plasma0.5mg/dL0.1-1.2 mg/dLNormalS
2026-10-09Glucose [Mass/volume] in Serum or Plasma91mg/dL70-99 mg/dLNormalS
2026-10-09Karnofsky Performance Status score80{score}S
2026-10-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-10-29Hemoglobin [Mass/volume] in Blood11.8g/dL12-15.5 g/dLLowS
2026-10-29Leukocytes [#/volume] in Blood by Automated count3.410*3/uL4-11 10*3/uLLowS
2026-10-29Neutrophils [#/volume] in Blood by Automated count1.910*3/uL1.5-7.7 10*3/uLNormalS
2026-10-29Lymphocytes [#/volume] in Blood by Automated count0.610*3/uL1-4 10*3/uLLowS
2026-10-29Platelets [#/volume] in Blood by Automated count12110*3/uL150-400 10*3/uLLowS
2026-10-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L7-35 U/LNormalS
2026-10-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-35 U/LNormalS
2026-10-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-06-29Body height180cmS
2026-06-29Body weight68kgS
2026-06-29Body mass index (BMI) [Ratio]21kg/m2S
2026-06-29Systolic blood pressure126mm[Hg]S
2026-06-29Diastolic blood pressure78mm[Hg]S
2026-06-29Heart rate72/minS
2026-06-29Respiratory rate14/minS
2026-06-29Body temperature36.7CelS
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-02Body height180cmS
2026-07-02Body weight67.8kgS
2026-07-02Body mass index (BMI) [Ratio]20.9kg/m2S
2026-07-02Systolic blood pressure134mm[Hg]S
2026-07-02Diastolic blood pressure82mm[Hg]S
2026-07-02Heart rate78/minS
2026-07-02Respiratory rate14/minS
2026-07-02Body temperature36.6CelS
2026-07-02Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-29Body height180cmS
2026-07-29Body weight69.4kgS
2026-07-29Body mass index (BMI) [Ratio]21.4kg/m2S
2026-07-29Systolic blood pressure132mm[Hg]S
2026-07-29Diastolic blood pressure80mm[Hg]S
2026-07-29Heart rate76/minS
2026-07-29Respiratory rate14/minS
2026-07-29Body temperature36.6CelS
2026-07-29Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-09-14Body height180cmS
2026-09-14Body weight67.2kgS
2026-09-14Body mass index (BMI) [Ratio]20.7kg/m2S
2026-09-14Systolic blood pressure118mm[Hg]S
2026-09-14Diastolic blood pressure74mm[Hg]S
2026-09-14Heart rate80/minS
2026-09-14Respiratory rate16/minS
2026-09-14Body temperature36.8CelS
2026-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-10-09Body height180cmS
2026-10-09Body weight66.6kgS
2026-10-09Body mass index (BMI) [Ratio]20.6kg/m2S
2026-10-09Systolic blood pressure120mm[Hg]S
2026-10-09Diastolic blood pressure76mm[Hg]S
2026-10-09Heart rate74/minS
2026-10-09Respiratory rate14/minS
2026-10-09Body temperature36.6CelS
2026-10-09Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-29Body height180cmS
2026-10-29Body weight66.9kgS
2026-10-29Body mass index (BMI) [Ratio]20.6kg/m2S
2026-10-29Systolic blood pressure118mm[Hg]S
2026-10-29Diastolic blood pressure72mm[Hg]S
2026-10-29Heart rate76/minS
2026-10-29Respiratory rate14/minS
2026-10-29Body temperature36.5CelS
2026-10-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-06-29New headaches, word-finding pauses and right-hand clumsiness in a woman of 54: neurologic examination, MRI of the brain booked for the next morning, and neuro-oncology review bookedfinishedS
2026-07-02MRI result: left frontal mass with edema; dexamethasone, CT staging, neuro-oncology consultation with neurosurgery, and preparation for awake craniotomyfinishedS
2026-07-29Review three weeks after awake craniotomy: pathology and molecular diagnosis, steroid taper, steroid-related hyperglycemia, falls, and the plan for radiotherapy with temozolomidefinishedS
2026-09-14End of six weeks of radiotherapy with daily temozolomide: blood counts, liver tests, Pneumocystis prophylaxis, fatigue, mood, tumor-treating fields and an early palliative care referralfinishedS
2026-10-09Post-chemoradiation MRI result, day 1 of adjuvant temozolomide, the start of tumor-treating fields, and the palliative care planfinishedS
2026-10-29Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Urgent neuro-oncology consultation within one week, together with neurosurgery, to review the brain MRI with her and plan diagnosis and treatment if it shows a tumorcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021S
New progressive focal neurologic symptoms are imaged promptly: MRI of the brain with and without contrast within 24 hours, with same-day emergency care if she worsens, has a seizure, vomits or becomes drowsy; blood count, chemistry and A1c; no driving until the cause is knowncompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021S
Dexamethasone only for edema causing symptoms, at the lowest effective dose (4 mg twice a day), with famotidine and glucose checks, and tapered off as soon as possible after surgerycompletedGL-EANO-GLIOMA-2021, GL-NCCN-CNS-2026S
CT of the chest, abdomen and pelvis to exclude another primary; functional MRI with tractography; awake craniotomy with language and motor mapping for maximal safe resection; MRI within 48 hours; integrated WHO CNS5 diagnosis with IDH1 R132H immunostaining and IDH1 and IDH2 sequencing, ATRX, TERT promoter, EGFR, chromosome 7 and 10, CDKN2A, histone H3, BRAF and MGMT promoter methylationcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-WHO-CNS5-2021S
No antiseizure prophylaxis, because she has had no seizure; seizure first aid taught to her and her household; levetiracetam if a seizure occurscompletedGL-SNO-EANO-AED-2021, GL-EANO-GLIOMA-2021S
Venous thromboembolism: mechanical and then low-molecular-weight heparin prophylaxis in hospital after surgery; no routine prophylaxis at home; she is taught the signs of leg clot and pulmonary embolism and to report them the same daycompletedGL-ASCO-VTE-2023, GL-NCCN-CNS-2026S
Radiotherapy 60 Gy in 30 fractions with temozolomide 75 mg/m2 daily, then six cycles of temozolomide 150 to 200 mg/m2 on days 1 to 5 of each 28-day cycle; Pneumocystis prophylaxis during concurrent treatment and while lymphopenia lasts; antiemetic before each dose; blood count weekly during chemoradiation and on day 22 of each adjuvant cycle; liver tests at baseline, mid-cycle 1 and before each cycle; MRI four weeks after radiotherapy and then every two to three months, read by RANO 2.0; clinical trial screeningcompletedGL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021, GL-STUPP-2005, GL-HEGI-2005, GL-TMZ-LABEL, GL-ASCO-SNO-2022, GL-RANO-2023S
Tumor-treating fields with adjuvant temozolomide, worn at least 18 hours a day, with scalp checks and skin carecompletedGL-EF14-2017, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021S
Falls and mobility from the first visit: home safety review, fall plan, physical therapy assessment once the treatment plan is set, and a check at every visit of strength in both legs, since new right-sided weakness adds to a left leg weakened by polio in childhood; watch for new weakness, fatigue or pain that could signal post-polio syndromecompletedGL-EFNS-PPS-2006, GL-EANO-GLIOMA-2021S
Early palliative care alongside cancer treatment: symptoms, coping, goals and advance care planning, and support for the people she choosescompletedGL-ASCO-PALL-2024, GL-NCCN-CNS-2026, GL-EANO-GLIOMA-2021S
Distress and depression screening at each visit, plain explanations with written information, and help to keep working as long as she wishes; she decides who receives informationcompletedGL-USPSTF-DEP-2023, GL-CMID-2026, GL-NCCN-CNS-2026S

Goals

GoalTargetStatusOutcomeProvenance
MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation2026-07-02completedMRI the next morning; consultation three days after the first visitS
Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength2026-07-29completedGross total resection of the enhancing tumor nine days after the first visit; speech back to normal within days and right-hand strength nearly normalS
Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule2026-09-14completedStarted 26 days after surgery; 30 fractions and 42 days of temozolomide completed without a breakS
Dexamethasone tapered off within five weeks of surgery, with glucose back to normal2026-09-14completedOff dexamethasone five weeks after surgery; glucose 96 mg/dL afterwardsS
No falls, and walking independently, through treatment2026-10-09completedNo falls; walks independently, with a cane only on uneven ground; home exercise program continuedS
Palliative care involved and her wishes recorded before adjuvant treatment begins2026-10-09completedPalliative care consultation and advance directive completed eleven days before adjuvant cycle 1S

Functional Status

Mental Status